Calidi Biotherapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.79 k

Shareholding (Jun 2025)

FII

1.82%

Held by 8 FIIs

DII

95.91%

Held by 2 DIIs

Promoter

0.04%

How big is Calidi Biotherapeutics, Inc.?

22-Jun-2025

As of Jun 18, Calidi Biotherapeutics, Inc. has a market capitalization of 9.86 million, with net sales of 0.00 million and a net profit of -20.05 million over the last four quarters. The company reported shareholder's funds of 1.53 million and total assets of 14.18 million as of Dec 24.

What does Calidi Biotherapeutics, Inc. do?

22-Jun-2025

Calidi Biotherapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $9.86 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a debt-to-equity ratio of -1.10.

Is Calidi Biotherapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 12, 2025, Calidi Biotherapeutics, Inc. shows a mildly bullish trend overall, despite mixed signals from various indicators, including bearish moving averages and Bollinger Bands, and significant underperformance compared to the S&P 500.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 8 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.47

Return on Equity

-1,161.22%

Price to Book

4.58

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-8.75%

6 Months

-65.88%

1 Year

-93.95%

2 Years

-99.43%

3 Years

-85.53%

4 Years

-85.15%

5 Years

0.0%

Calidi Biotherapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Calidi Biotherapeutics, Inc. technically bullish or bearish?

As of 12 August 2025, the technical trend for Calidi Biotherapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD remains bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are bearish, and both the weekly and monthly Bollinger Bands are bearish as well. The KST shows bearish signals in both time frames, and Dow Theory indicates no trend weekly but bearish monthly. However, the On-Balance Volume (OBV) is mildly bullish on a weekly basis, suggesting some accumulation. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -88.55% versus the S&P's 12.22%, and a one-year return of -88.14% compared to the S&P's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is weak due to the bearish indicators present in multiple time frames....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-207.52%

EBIT to Interest (avg)

-9.35

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.10

Sales to Capital Employed (avg)

0.00

Tax Ratio

0.06%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

22.03%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.63

EV to EBIT

-0.18

EV to EBITDA

-0.20

EV to Capital Employed

-3.71

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-296.84%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (2.22%)

Foreign Institutions

Held by 8 Foreign Institutions (1.82%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 53.60% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.30",
          "val2": "-5.40",
          "chgp": "1.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.80",
          "val2": "-5.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 23.97% vs -14.96% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.20",
          "val2": "-27.70",
          "chgp": "27.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "3.70",
          "chgp": "-75.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.70",
          "chgp": "-57.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.20",
          "val2": "-29.20",
          "chgp": "23.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.30

-5.40

1.85%

Interest

0.10

0.30

-66.67%

Exceptional Items

-0.00

0.10

-100.00%

Consolidate Net Profit

-5.80

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.00% vs 53.60% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-20.20

-27.70

27.08%

Interest

0.90

3.70

-75.68%

Exceptional Items

0.30

0.70

-57.14%

Consolidate Net Profit

-22.20

-29.20

23.97%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 23.97% vs -14.96% in Dec 2023

All Annual Results

Company CV

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Calidi Biotherapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Calidi Biotherapeutics, Inc.?

Watch in Real-Time

What does Calidi Biotherapeutics, Inc. do?

Is Calidi Biotherapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Calidi Biotherapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Calidi Biotherapeutics, Inc.

Company Coordinates